News from AIDS 2010

aidsmap news from AIDS 2010

Three tactics to stem the tide of criminal prosecutions

Scientists, lawyers and advocates have been able to reduce unwarranted prosecutions of HIV exposure and transmission in three European jurisdictions by employing three distinct approaches, Robert James

Published: 29 July 2010
By: Roger Pebody

Less than 10% of East European prevention spending is for vulnerable groups

In the countries of Eastern Europe and Central Asia, 89% of national government funding for HIV prevention goes on programmes for the general population, although most countries’

Published: 28 July 2010
By: Roger Pebody

New studies strengthen evidence that drug addiction is a disease of the brain; substitution therapy necessary

Two scientific lectures presented at the Eighteenth International AIDS Conference in Vienna last week, demonstrated that drug use in and of itself is linked to increased

Published: 27 July 2010
By: Mara Kardas-Nelson

Evidence-based treatment of drug users needed to strengthen human rights, stem drug use, and halt the HIV epidemic

Drug policies based on ideology rather than science are fueling human rights abuses of drug users, according to a panel of experts speaking at last week’s Eighteenth

Published: 27 July 2010
By: Mara Kardas-Nelson

'The business of public health': new research on financing of HIV programmes

At the International AIDS Conference in Vienna, a session on the financing of HIV programmes yielded important results about the long-term costs and health impacts of

Published: 27 July 2010
By: Rebecca Hodes

Mass testing campaign unjustified if people fail to receive treatment, activist argues

South Africa’s campaign to test 15 million people for HIV in one year risks being implemented in a way that undermines people’s human rights, the activist Mark

Published: 27 July 2010
By: Roger Pebody

Good results seen with NRTI-sparing regimens of atazanavir plus newer drug classes

Combination antiretroviral regimens containing atazanavir (Reyataz) plus drugs from two newer classes – the integrase inhibitor raltegravir (Isentress) and the CCR5 antagonist maraviroc (Celsentri) – demonstrated promising anti-HIV activity,

Published: 26 July 2010
By: Liz Highleyman

Neurocognitive impairment linked to prior low CD4 cell count, even if on current suppressive HIV treatment

People who had a low CD4 cell count in the past remain at greater risk for HIV-related neurocognitive impairment even after they start antiretroviral therapy and their

Published: 26 July 2010
By: Liz Highleyman

Prevention strategies need to target both early and chronic HIV infection

An analysis of transmission patterns in Lilongwe, Malawi shows that even if a highly effective HIV prevention intervention could reach 75% of people in chronic infection, it

Published: 26 July 2010
By: Roger Pebody

CASCADE analysis finds antiretroviral treatment benefits are evident below CD4 count of 500, uncertain above this level

Starting antiretroviral therapy with a CD4 cell count between 350 and 500 cells/mm3 reduces the likelihood of HIV disease progression and death relative to initiation below 350 cells/mm3,

Published: 23 July 2010
By: Liz Highleyman

Video of satellite meeting

View the presentations from the meeting 'Criminalisation of HIV exposure and transmission'.

View the presentations >

More coverage of the conference

Two other official partners of the conference provided coverage and analysis online.

Clinical Care Options (CCO) provided audio highlights, capsule summaries and downloadable slidesets, while the Kaiser Family Foundation provided webcasting from conference sessions.